Objective-Smooth muscle progenitor cells (SMPCs) were intriguingly shown to act as a double-edged sword in the pathogenesis of atherosclerosis. To fully clarify the roles of SMPCs in atherosclerosis, a distinct panel of SMPC surface markers is mandatory to be developed. Methods and Results-Microarray gene expression analyses were used to discover potential surface markers of SMPCs.
A ccumulating evidence indicates the role of circulating vascular progenitor cells in atherosclerosis, neointima hyperplasia after arterial injury, and transplant atherosclerosis. 1 It is well accepted that endothelial progenitor cells (EPCs) participate in arterial repair and angiogenesis after ischemia by homing to the injured sites and differentiating into endothelial cells. 2, 3 Smooth muscle progenitor cells (SMPCs) were shown to expedite lesion formation during restenosis and also serve to stabilize atherosclerotic plaques by producing extracellular matrix proteins. [4] [5] [6] [7] [8] SMPCs appear to act as a doubleedged sword in the pathogenesis of atherosclerosis. However, how SMPCs mediate opposite aspects of atherosclerosis and, accordingly, the significance of manipulating SMPCs in clinical settings remain poorly defined.
The identification and pathophysiological exploration of SMPCs have encountered rigorous challenges. The main obstacle is primarily attributed to the difficulty in defining and tracking SMPCs in vivo at different stages. Fully understanding the contributions of SMPCs to vascular maintenance and repair in early and late stages depends on further elucidation of SMPC-specific markers. Current strategies of identifying SMPCs are based on immunostaining intracellular smooth muscle-specific proteins or putative surface markers, as proposed in several reports. [9] [10] [11] The heterogeneous characteristics and divergent phenotypes of SMPCs used in different studies fostered limited progress in understanding SMPCs in various pathological environments. The present study adopted a microarray approach to develop a distinct panel of SMPC surface markers, which are not expressed by EPCs, although both of them are derived from peripheral blood. These markers explored the heterogeneity of peripheral blood-derived SMPCs with different functional capacities in response to cues provided by the microenvironment after vascular injury.
Materials and Methods
An expanded Materials and Methods section can be found in the online-only Data Supplement.
Cultivation of Late EPCs, SMPCs, and Other Cells
Peripheral blood mononuclear cells (PBMNCs) were isolated from whole blood by density gradient centrifugation with Ficoll separating solution (Sigma-Aldrich, St Louis, MO). After resuspension in EGM-V2 (PromoCell, Heidelberg, Germany), 1×10 7 mononuclear cells/cm 2 were plated on fibronectin-coated dishes. The method of producing EPCs was described before. 1, 12 To cultivate SMPCs, PBMNCs were allowed to adhere and grow for 7 days in EGM-V2, supplemented with 10% fetal bovine serum. Full medium was replaced every 3 days thereafter. Human aortic smooth muscle cells (Cascade Biologics, Portland, OR) were cultured in mediun 231 with cell-growth supplements.
Microarray Processing
RNA isolated from SMPCs and EPCs was labeled with cyanine 5 and cyanine 3 (CyDye; PerkinElmer, Waltham, MA), respectively. RNA was amplified by a low RNA input fluor linear amp kit (Agilent Technologies, Santa Clara, CA) and labeled with cyanine 3 or cyanine 5) during the in vitro transcription process. Microarrays were scanned with an Agilent microarray scanner (Agilent Technologies) at 535 nm for cyanine 3 and 625 nm for cyanine 5.
Results

Characteristics of SMPC and EPC Lines
During cultivation of vascular progenitor cells from PBMNCs, colonies of SMPCs and EPCs were evident ≈1 to 2 weeks after PBMNCs were plated. SMPCs appeared as spindle-shaped colonies and finally spread out in a hill-and-valley confluent growth pattern ( Figure 1A , left and middle). After SMPCs were confluent or stimulated by transforming growth factor (TGF)-β for differentiation, SMPCs changed from α-smooth muscle actin (SMA) low to α-SMA high ( Figure 1A , right). EPCs became confluent at 4 weeks and grew with a cobblestone appearance ( Figure 1B) . Occasionally, SMPC and EPC colonies separately outgrew the other one on the same dish, demonstrating that PBMNCs comprise different progenitor populations. However, in most cases, outgrowths of SMPCs were mixed with EPCs ( Figure 1C ).
Phenotypes of Human SMPCs and EPCs
Based on established surface markers of EPCs and intracellular markers of SMPCs, pure SMPC and EPC lines were defined. SMPCs were positive for α-SMA, smooth muscle myosin heavy chain (SM-MHC), calponin, and desmin, and negative for CD31, vascular endothelial cadherin, CD146, kinase insert domain receptor, Tie-2, ulex europaeus agglutinin 1, and c-kit ( Figure 1D and 1E ). In addition, SMPCs were demonstrated to contract the collagen gel in response to angiotensin II stimulation ( Figure 1F ). In total, 5 SMPC (from 4 volunteers and 1 patient after acute myocardial infarction; 2 men and 3 women, age 45±8 years) and 4 EPC lines (from 2 volunteers and 2 patients with coronary artery disease; 2 men and 2 women, age 47±3 years) were obtained for the following studies.
Microarray Gene Expression Analysis
To identify the potential surface markers of SMPCs, we conducted a microarray gene expression analysis on the 5 SMPC and 4 EPC lines. Hierarchical clustering and expression level analyses of the microarray data set showed that SMPCs were distinct from EPCs (Figure 2A and 2B) . A stringent analysis was performed to select genes that were expressed in SMPCs at a higher level than in EPCs (>16-fold with a P<0.005). This gave a total of 231 genes, including 12 membrane genes, 83 secretion genes, 55 cytoplasm genes, 31 nuclear genes, and 50 others. The microarray expression data for the genes encoding membrane proteins are graphically shown in Figure 2C and Table I in the online-only Data Supplement.
These genes include PDGFR-α and -β (platelet-derived growth factor receptor), which are typical receptors expressed on smooth muscle cells, LRP1 (low-density lipoprotein receptor-related protein), and interleukin 1 receptor, type II, which is a receptor of interleukin 1. Also included are CPM (carboxypeptidase M), CA12 (carbonic anhydrase 12), and RAMP1 (receptor activity-modifying protein 1). Other markers of interest included 6 transmembrane epithelial antigen of the prostate 2, phosphoprotein-glycosphingolipid microdomains 1, prostaglandin E2 receptor, thombospondin 2, and sushi domain-containing protein 2. Because no appropriate antibodies applied to the flow cytometry study were developed for 6 transmembrane epithelial antigen of the prostate 2, phosphoprotein-glycosphingolipid microdomains 1, prostaglandin E2 receptor, or thombospondin 2, no further confirmatory experiments were done on those genes.
Verification by Quantitative Real-Time Polymerase Chain Reaction and Western Blotting
For verification, quantitative real-time polymerase chain reaction (TaqMan PCR; TaqMan) and Western blotting were performed on another 4 SMPC and 3 EPC lines. All TaqMan results were in agreement with the microarray data except for sushi domain-containing protein 2 ( Figure 2D ). Western blotting demonstrated that PDGFR-α and -β, LRP1, CPM, CA12, and RAMP1 were expressed by SMPCs but not by EPCs ( Figure 2E ). However, interleukin 1 receptor, type 2 was expressed by both SMPCs and EPCs.
Surface Markers Applied to Flow Cytometry
All verified surface markers were then tested by flow cytometry (Figure 3 ). Forward-and side-scatter analyses demonstrated 3 SMPC populations (R1, R2, and R3), which were all positive for PDGFR-β, CPM, and LRP1 but negative for CD31, junctional adhesion molecule 1 (endothelial markers) ( Figure 3A) , and Mac3 (a macrophage marker) ( Figure IA and IB in the onlineonly Data Supplement). The R1 population represents small SMPCs with low granularity, the R2 population represents small SMPCs with high granularity, and the R3 population represents large SMPCs with high granularity. Expressions of SM-MHC, calponin, and myocardin were noted in cell populations R1 and R3 but not in R2. CA12 and RAMP1 were only expressed by SMPCs (R2 and R3). After TGF-β was introduced to stimulate differentiation ( Figure 3B ), the SMPC (R2) population disappeared. In addition, expressions of CA12 and RAMP1 were remarkably downregulated. Figure  3C and Figure IA in the online-only Data Supplement revealed that none of these SMPC markers were expressed by EPCs except for CD54. As a positive control, human aortic smooth muscle cells were positive for PDGFR-α and -β, CPM, and CD54 but negative for CD31, junctional adhesion molecule 1, CA12, and RAMP1. LRP1 was weakly expressed. Fresh PBMNCs were strongly positive for CD14, CD54, junctional adhesion molecule 1, and CD31 but were positive at very low incidences for CA12, CPM, LRP1, and RAMP1.
Immunocytochemical and Histochemical Staining
In Figure 4 , immunostaining demonstrated that SMPCs, but not EPCs, were positive for CA12, CPM, RAMP1, and LRP1, both in vitro ( Figure 4A ) and in vivo ( Figure 4B and Figure II in the online-only Data Supplement, late SMPCs were injected into severe combined immunodeficiency/nonobese diabetic mice after wire injury to the femoral artery). To estimate the contribution of SMPCs derived from peripheral blood to neointimal formation, an animal model was created by injecting human PBMNCs into nonobese diabetic/severe combined immunodeficiency mice via a tail vein 4 days after wire injury to the femoral artery ( Figure 4C ). Confocal immunostaining performed on vessels harvested 4 days after cell injection showed that scattered HLA-ABC ++ human cells were adherent to the injured vascular surface, and some of them coexpressed both PDGFR-β and SMPC surface markers, including CPM, LRP1, CA12, and RAMP1 ( Figure 4C and Figure III 
Functions of SMPC Surface Markers
RAMP1 is functional after forming a heterodimer with the calcitonin-receptor-like receptor to respond to the calcitonin gene-related peptide (CGRP). Pretreatment with CGRP (100 nmol/L) significantly attenuated the proinflammatory effect of lipopolysaccharide (10 ng/mL) on gene expressions of monocyte chemotactic protein-1, interleukin-1β, interleukin-6, and interleukin-2 by SMPCs ( Figure 5A ). CGRP also attenuated the expression of extracellular matrix genes by SMPCs in response to lipopolysaccharide stimulation, including collagen α1 (V), fibronectin, and periostin ( Figure 5B ). However, these effects of CGRP were not noted in RAMP1 − SMPCs. The presence of CPM was associated with lower migratory function of SMPCs ( Figure 5C ) but not with the proliferative capacity ( Figure 5D ). However, acetazolamide, a carbonic anhydrase inhibitor, significantly decreased the amount of SMPCs undergoing apoptosis in a prolonged hypoxic environment ( Figure 5E ). Figure 3B demonstrates that TGF-β remarkably upregulated the expression intensity of PDGFR-β by late SMPCs but did not stimulate the expression of PDGFR-β by EPCs ( Figure IC in the online-only Data Supplement). We hypothesized that the expression level of PDGFR-β on circulating SMPCs could also be amplified by TGF-β. To clarify this, purified PBMNCs were cultivated in DMEM with and without TGF-β for 7 days. On day 0, the fluorescence intensity of PDGFR-β was too low to clearly enumerate the number of PDGFR-β + cells ( Figure VII in the online-only Data Supplement). Without TGF-β, PDGFR-β + cells were not detected throughout the 7-day cultivation period. With TGF-β, PDGFR-β + cells with significantly increased expression intensity were noted from day 3 ( Figure 6A and 6B, and Figure VII in the online-only Data Supplement). In addition, PDGFR-β + cells were located at a distinct region (R2 in Figure 6A ) that appeared only in the TGF-β-treated group with cells characterized by a smaller size and increased granularity compared with the lymphocyte population ( Figure 6B , area X1 in R2). Furthermore, some of the PDGFR-β + cells were also positive for CA12, CPM, RAMP1, and LRP1 ( Figure 6B ). Accordingly, early SMPCs, namely SMPCe, were defined by PDGFR-β + along with CPM Then, SMPCe were quantified in a variety of patient populations. The number of SMPCe was higher in young volunteers compared with aging subjects with normal coronary angiograms ( Figure 6C ). Although at similar ages, patients with unstable angina had remarkably higher numbers of SMPCe compared with those with normal coronary angiograms. SMPCe numbers did not significantly differ between young volunteers and patients with unstable angina. However, numbers of PDGFR-β SMPCe levels were noted after the intervention ( Figure 6D ). Type 1 patients presented preexisting unstable angina before the acute myocardial infarction and had higher SMPCe numbers at the time of the coronary intervention. However, levels had remarkably decreased the following day and then gradually increased. Types 2 and 3 presented with acute onset of acute myocardial infarction with very low levels at presentation, and had, however, increased numbers of SMPCe at either early or late time points, respectively.
Defining Markers of Early SMPCs
Discussion
Our study demonstrated that SMPCs contain heterogeneous subpopulations expressing surface markers distinct from EPCs. Different surface markers exhibit various functions associated with anti-inflammation, migration, tolerability of hypoxia, and extracellular matrix synthesis, providing a solution to interpret the wide variations of SMPC functions in the literature. Our data also shed light on a way to quantify circulating SMPCs and provide a platform for studying roles of SMPCs in a variety of cardiovascular diseases.
Critical Obstacles in SMPC Research
Simper et al 8 However, from our experience in performing flow cytometry, the expression intensity of PDGFR-β on circulating mononuclear cells is low and not clearly discriminated from negative cells, and the enumeration of CD34 + cells is highly experience-and technique-dependent. SM-MHC is a protein expressed in the late stage of full smooth muscle differentiation. Furthermore, identifying SM-MHC and other intracellular proteins specific to smooth muscle cells need cell permeabilization, which limits subsequent applications of those cells. To move SMPC research to the next step depends on exploring novel SMPC-specific surface markers.
Surface Markers of Heterogeneous SMPCs Exhibit Various Functions
In the literature, reported functions of SMPCs are inconsistent, even contradictory. [5] [6] [7] [8] Our data revealed that peripheral blood-derived SMPCs actually contain heterogeneous populations with different panels of surface markers. Interestingly, in addition to PDGFR-β, all the selected markers were linked to possible roles of SMPCs in atherosclerosis. CPM, a membrane-bound metallo-carboxypeptidase, can reportedly degrade or activate several extracellular peptides including bradykinin, epidermal growth factor, and some growth factors, and mediates vasodilatation. 13 Our data demonstrated that the expression of CPM on SMPCs was related to a decreased migration capacity. RAMP1, a type I transmembrane protein, is required to transport the calcitonin-receptor-like receptor to plasma membranes to function as a CGRP receptor, which is associated with inhibiting bone resorption and inducing vasodilation. 14 Our study showed that RAMP1 was associated with the function of SMPCs in extracellular matrix synthesis and anti-inflammation. CA12 is an extracellular enzyme that catalyzes the reversible hydration of CO 2 and is involved in regulating microenvironmental acidity. Acidification of the extracellular environment favors invasion and migration; however, alkalinization of the cytoplasm maintains cell proliferation and survival. 15, 16 In addition, CA12 was demonstrated to be related to arterial calcification 17 and increases the tolerance of cells to a hypoxic environment as shown in our study. LRP1, a member of the low-density lipoprotein receptor family, is able to recognize more than 30 distinct ligands and plays diverse roles in various biological processes including lipoprotein metabolism and protection against atherosclerosis. 18 Previous reports suggested that LRP1 is abundantly expressed in vascular smooth muscle cells but is not as abundant in the endothelium.
19,20
Enumeration of SMPCe
The prevalence of SMPC in circulation is rare. To enumerate PDGFR-β + cells is difficult because the fluorescence intensity is low if no preconditioning process is applied to the cells before fluorescence-activated cell sorting. Previously, Gronwald et al 21 showed that treatment with TGF-β for 24 hours transiently abolished the binding affinity of PDGFR-β expressed on fibroblasts. Our data demonstrated a remarkably enhanced expression intensity of PDGFR-β on peripheral blood-derived SMPCe after they were exposed to TGF-β for 3 days. This phenomenon favorably improved the enumeration of circulating SMPCe by flow cytometry. The assay developed in our study provides a platform for quantifying SMPCe similar to using the colony-forming unit assay for EPCs.
The panel of SMPC surface markers we provided indicated the presence of heterogeneous subpopulations of SMPCs. Although expressions of these surface markers are also present in other somatic cells, a combination of these markers with PDGFR-β helped define heterogeneous functions of SMPCs in vivo. TGF-β is secreted by platelets and is abundantly present at the site of platelet-rich vascular lesions. 22 The novelty of this enumeration assay is evident based on the finding that the expression of PDGFR-β and the panel of SMPC surface markers on human PBMNCs were silenced in circulation but were strongly activated only after they adhered to the surface of injured vessels. The potential of circulating cells being able to differentiate into SMPCs was suggested by our assay simulating a sophisticated environmental cue, although the cue is as yet unraveled. Previously, Sugiyama et al 9 suggested that CD105 is a surface marker of SMPCe. Actually, CD105 is a coreceptor of TGF-β. One could argue that the SMPCe we defined might not exactly be the outgrowth of SMPCs on Circulating mononuclear cells expressing CPM, CA12, RAMP1, and LRP1 were rare. However, whether this panel of markers can be used to enumerate and separate SMPCe from fresh PBMNCs needs to be investigated in future studies. However, our data showed that both human aortic smooth muscle cells and SMPCs expressed CPM and LRP1. Only SMPCs expressed CA12 and RAMP1. These data suggest that PDGFR-β + CPM + and PDGFR-β + LRP1 + can be used as markers for circulating SMCs and SMPCs. PDGFR-β + along with CA12 + and RAMP1 + can specifically be used as markers for circulating SMPCs. However, well-differentiated SMPCs lose CA12 and RAMP1. It is hard to define SMPCs on a chronic atheroma. The surface markers identified in this study for SMPCs can only be used at the very early stage of developing a new and unstable plaque. This finding is consistent with the notion described by Yu et al 23 that phenotypes of SMPCs may disappear after an atheroma is well established.
Findings in a Human Study
Cytokines released by ischemic stress probably mobilize progenitors other than EPCs. It was shown that the number of late EPC colonies is higher in patients with coronary artery disease than control subjects. 24 However, as shown in this study, circulating numbers and dynamic changes of SMPCs are very sophisticated. In patients without coronary artery disease, the circulating numbers of SMPCs were higher in young volunteers but lower in the elderly, suggesting that SMPCs play a role in tissue repair related to aging. Interestingly, the remarkably increased SMPCe numbers in patients with unstable angina suggested the presence of underlying mobilization mechanisms in response to the disease pathophysiology. However, PDGFR-β + SMPCs in these patients were probably characterized by stronger migratory and lower anti-inflammatory capacities as shown by lower expressions of CPM and RAMP1. These interplays explain the opposite roles reported in the literature. [5] [6] [7] [8] In patients with acute myocardial infarction, we noted 3 different patterns of circulating SMPC dynamics. In response to the presence or absence of preexisting myocardial ischemic stress, patients presented different circulating SMPCe levels. The immediate decrease in SMPCe levels after coronary intervention in type 1 patients may have been associated with the homing of a substantial amount of SMPCs to the reperfused infarct-related artery. The timing of the increase in SMPC numbers in types 2 and 3 was probably related to the compromise between the strength of the mobilizing impulse and the amount of homing cells. These findings provide resolution in explaining the conflicting differences between previous reports. The clinical impacts of different dynamics of circulating SMPCs are still to be elucidated.
Clinical Applications
Atherosclerosis is a process extending over decades. Thus, even a modest subpopulation of circulating cells may contribute significantly to its pathophysiology. 25 Previously, Yu et al 23 showed that bone marrow-derived smooth muscle-like cells are infrequent in advanced primary atherosclerotic plaques but still promote atherosclerosis. Although it is evident that outgrowth SMPCs exist in ex vivo cultivation, these cells are rare and may even arise from extra-bone marrow sources. Currently, SMPCs are defined by immunostaining of intracellular cytoskeletal structures after cell permeabilization, which causes cell death with no chance of further manipulations. Although PDGF receptors are well-established surface markers of SMCs, combining other sets of surface markers provides the following benefits. First, dual markers for SMPCs give rise to a more specific definition, establishing a platform for global SMPC research. Second, different markers define heterogeneous SMPC populations with different functions. Last, purifying SMPCs by a marker other than PDGFR-β helps selected expansion by PDGF-BB.
